<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font23 { font-size : 23; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font29 { font-size : 29; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">antibody </span>
   <span class="font29">human </span>
   <span class="font23">antibodies </span>
   <span class="font17">cell </span>
   <span class="font16">IgG </span>
   <span class="font16">cancer </span>
   <span class="font15">mAbs </span>
   <span class="font15">phage </span>
   <span class="font15">cells </span>
   <span class="font15">display </span>
   <span class="font15">treatment </span>
   <span class="font14">therapeutic </span>
   <span class="font14">mice </span>
   <span class="font14">Human </span>
   <span class="font14">single </span>
   <span class="font14">used </span>
   <span class="font14">affinity </span>
   <span class="font13">approved </span>
   <span class="font13">Hybridoma </span>
   <span class="font13">monoclonal </span>
   <span class="font13">clinical </span>
   <span class="font13">Humanized </span>
   <span class="font13">patients </span>
   <span class="font13">drugs </span>
   <span class="font13">Inc. </span>
   <span class="font12">Phage </span>
   <span class="font12">chain </span>
   <span class="font12">fully </span>
   <span class="font12">Nat </span>
   <span class="font12">libraries </span>
   <span class="font12">mAb </span>
   <span class="font12">mouse </span>
   <span class="font12">Phase </span>
   <span class="font12">Antibody </span>
   <span class="font12">library </span>
   <span class="font12">transgenic </span>
   <span class="font12">Cancer </span>
   <span class="font12">FDA </span>
   <span class="font12">murine </span>
   <span class="font12">receptor </span>
   <span class="font12">virus </span>
   <span class="font12">Immunol </span>
   <span class="font12">growth </span>
   <span class="font12">humanized </span>
   <span class="font12">antigen </span>
   <span class="font12">development </span>
   <span class="font12">drug </span>
   <span class="font12">disease </span>
   <span class="font12">factor </span>
   <span class="font12">immune </span>
   <span class="font12">Transgenic </span>
   <span class="font12">targeting </span>
   <span class="font12">binding </span>
   <span class="font12">selection </span>
   <span class="font12">tumor </span>
   <span class="font12">variable </span>
   <span class="font11">Fab </span>
   <span class="font11">method </span>
   <span class="font11">new </span>
   <span class="font11">high </span>
   <span class="font11">phage-displayed </span>
   <span class="font11">generation </span>
   <span class="font11">protein </span>
   <span class="font11">Med </span>
   <span class="font11">antigens </span>
   <span class="font11">developed </span>
   <span class="font11">genes </span>
   <span class="font11">maturation </span>
   <span class="font11">region </span>
   <span class="font11">study </span>
   <span class="font11">use </span>
   <span class="font11">using </span>
   <span class="font11">(Fig. </span>
   <span class="font11">Pharmaceuticals </span>
   <span class="font11">generated </span>
   <span class="font11">specific </span>
   <span class="font11">target </span>
   <span class="font11">{border-style </span>
   <span class="font11">(Table </span>
   <span class="font11">arthritis </span>
   <span class="font11">efficacy </span>
   <span class="font11">heavy </span>
   <span class="font11">light </span>
   <span class="font11">novel </span>
   <span class="font11">Biol </span>
   <span class="font11">IL- </span>
   <span class="font11">Rev </span>
   <span class="font11">neutralizing </span>
   <span class="font11">px;} </span>
   <span class="font11">scFv </span>
   <span class="font11">technology </span>
   <span class="font11">#ffffff;} </span>
   <span class="font11">Clin </span>
   <span class="font11">Methods </span>
   <span class="font11">Mol </span>
   <span class="font11">Roche, </span>
   <span class="font11">Sci </span>
   <span class="font11">antibodies. </span>
   <span class="font11">billion </span>
   <span class="font11">bispecific </span>
   <span class="font11">gene </span>
   <span class="font11">large </span>
   <span class="font11">Engl </span>
   <span class="font11">antibody, </span>
   <span class="font11">chimeric </span>
   <span class="font11">currently </span>
   <span class="font11">including </span>
   <span class="font11">./NEJMoa </span>
   <span class="font11">Biotechnol </span>
   <span class="font11">CDR </span>
   <span class="font11">Chen </span>
   <span class="font11">PD- </span>
   <span class="font11">XenoMouse </span>
   <span class="font11">antibodies, </span>
   <span class="font11">different </span>
   <span class="font11">generate </span>
   <span class="font11">identification </span>
   <span class="font11">influenza </span>
   <span class="font11">isolation </span>
   <span class="font11">rheumatoid </span>
   <span class="font11">therapeutics </span>
   <span class="font11">clones </span>
   <span class="font11">constant </span>
   <span class="font11">engineering </span>
   <span class="font11">lung </span>
   <span class="font11">market </span>
   <span class="font11">memory </span>
   <span class="font11">./s--- </span>
   <span class="font11">Antibodies </span>
   <span class="font11">Biotech </span>
   <span class="font11">Chimeric </span>
   <span class="font11">Hoffmann-La </span>
   <span class="font11">III </span>
   <span class="font11">IgH </span>
   <span class="font11">Johnson </span>
   <span class="font11">Monoclonal </span>
   <span class="font11">Technology </span>
   <span class="font11">antigen-specific </span>
   <span class="font11">derived </span>
   <span class="font11">metastatic </span>
   <span class="font11">potential </span>
   <span class="font11">results </span>
   <span class="font11">trial </span>
   <span class="font10">Adalimumab </span>
   <span class="font10">Drug </span>
   <span class="font10">PD-L </span>
   <span class="font10">Res </span>
   <span class="font10">Single </span>
   <span class="font10">Wang </span>
   <span class="font10">approval </span>
   <span class="font10">binds </span>
   <span class="font10">humanization </span>
   <span class="font10">leukemia </span>
   <span class="font10">mutations </span>
   <span class="font10">psoriasis </span>
   <span class="font10">rapid </span>
   <span class="font10">response </span>
   <span class="font10">safety </span>
   <span class="font10">sequences </span>
   <span class="font10">technique </span>
   <span class="font10">therapy </span>
   <span class="font10">vitro </span>
   <span class="font10">./.. </span>
   <span class="font10">EGFR </span>
   <span class="font10">Ltd./Genentech </span>
   <span class="font10">Novartis </span>
   <span class="font10">animals </span>
   <span class="font10">antibodies: </span>
   <span class="font10">combination </span>
   <span class="font10">discovery </span>
   <span class="font10">diseases. </span>
   <span class="font10">example, </span>
   <span class="font10">highly </span>
   <span class="font10">immunogenicity </span>
   <span class="font10">immunoglobulin </span>
   <span class="font10">lymphoma </span>
   <span class="font10">phase </span>
   <span class="font10">studies </span>
   <span class="font10">trials </span>
   <span class="font10">./S-()- </span>
   <span class="font10">Acad </span>
   <span class="font10">Bristol-Myers </span>
   <span class="font10">Cambridge </span>
   <span class="font10">HuMabMouse </span>
   <span class="font10">Liu </span>
   <span class="font10">MAbs. </span>
   <span class="font10">Natl </span>
   <span class="font10">Oncol </span>
   <span class="font10">Proc </span>
   <span class="font10">Regeneron </span>
   <span class="font10">Smith </span>
   <span class="font10">Ther </span>
   <span class="font10">Therapeutic </span>
   <span class="font10">VEGFR </span>
   <span class="font10">activity </span>
   <span class="font10">delivery </span>
   <span class="font10">domain </span>
   <span class="font10">expression </span>
   <span class="font10">fragments </span>
   <span class="font10">major </span>
   <span class="font10">prevention </span>
   <span class="font10">products </span>
   <span class="font10">provide </span>
   <span class="font10">review </span>
   <span class="font10">sales </span>
   <span class="font10">sequence </span>
   <span class="font10">Amgen </span>
   <span class="font10">Chem </span>
   <span class="font10">Dis </span>
   <span class="font10">However, </span>
   <span class="font10">Ltd. </span>
   <span class="font10">Pembrolizumab </span>
   <span class="font10">analysis </span>
   <span class="font10">applications </span>
   <span class="font10">based </span>
   <span class="font10">cancer, </span>
   <span class="font10">cells, </span>
   <span class="font10">diseases </span>
   <span class="font10">endothelial </span>
   <span class="font10">enhance </span>
   <span class="font10">high-affinity </span>
   <span class="font10">hybridoma </span>
   <span class="font10">identify </span>
   <span class="font10">infection </span>
   <span class="font10">naïve </span>
   <span class="font10">number </span>
   <span class="font10">production </span>
   <span class="font10">regions </span>
   <span class="font10">repertoire </span>
   <span class="font10">respiratory </span>
   <span class="font10">responses </span>
   <span class="font10">successful </span>
   <span class="font10">surface </span>
   <span class="font10">targets </span>
   <span class="font10">treat </span>
   <span class="font10">vivo </span>
   <span class="font10">B-cell </span>
   <span class="font10">CDRs </span>
   <span class="font10">CGRP </span>
   <span class="font10">Colorectal </span>
   <span class="font10">Crohn’s </span>
   <span class="font10">Eli </span>
   <span class="font10">Moreover, </span>
   <span class="font10">Nature. </span>
   <span class="font10">Pharmaceutical </span>
   <span class="font10">Psoriasis </span>
   <span class="font10">Roche </span>
   <span class="font10">TNFα </span>
   <span class="font10">Table </span>
   <span class="font10">allowing </span>
   <span class="font10">anti-CD </span>
   <span class="font10">approach </span>
   <span class="font10">autoimmune </span>
   <span class="font10">cloning </span>
   <span class="font10">colorectal </span>
   <span class="font10">compared </span>
   <span class="font10">containing </span>
   <span class="font10">direct </span>
   <span class="font10">diseases, </span>
   <span class="font10">domains </span>
   <span class="font10">drugs, </span>
   <span class="font10">early </span>
   <span class="font10">effector </span>
   <span class="font10">effects </span>
   <span class="font10">efficient </span>
   <span class="font10">fragment </span>
   <span class="font10">framework </span>
   <span class="font10">introduced </span>
   <span class="font10">isolated </span>
   <span class="font10">methods </span>
   <span class="font10">order </span>
   <span class="font10">px; </span>
   <span class="font10">screening </span>
   <span class="font10">solid </span>
   <span class="font10">somatic </span>
   <span class="font10">syndrome </span>
   <span class="font10">techniques </span>
   <span class="font10">tumors </span>
   <span class="font10">{font-family </span>
   <span class="font10">(.%), </span>
   <span class="font10">Affinity </span>
   <span class="font10">Avelumab </span>
   <span class="font10">Cell </span>
   <span class="font10">Cellular </span>
   <span class="font10">Chronic </span>
   <span class="font10">Clinical </span>
   <span class="font10">Currently, </span>
   <span class="font10">Generation </span>
   <span class="font10">HIV- </span>
   <span class="font10">Lee </span>
   <span class="font10">Nivolumab </span>
   <span class="font10">Opin </span>
   <span class="font10">Rheumatoid </span>
   <span class="font10">Science. </span>
   <span class="font10">Trastuzumab </span>
   <span class="font10">Winter </span>
   <span class="font10">Zhang </span>
   <span class="font10">antibody-based </span>
   <span class="font10">arthritis, </span>
   <span class="font10">biopanning </span>
   <span class="font10">blood </span>
   <span class="font10">breast </span>
   <span class="font10">broadly </span>
   <span class="font10">cells. </span>
   <span class="font10">design </span>
   <span class="font10">diversity </span>
   <span class="font10">epidermal </span>
   <span class="font10">expressed </span>
   <span class="font10">font-size </span>
   <span class="font10">identified </span>
   <span class="font10">improve </span>
   <span class="font10">infected </span>
   <span class="font10">infectious </span>
   <span class="font10">inflammatory </span>
   <span class="font10">kappa </span>
   <span class="font10">lymphocytic </span>
   <span class="font10">mAbs, </span>
   <span class="font10">mAbs. </span>
   <span class="font10">natural </span>
   <span class="font10">process </span>
   <span class="font10">produce </span>
   <span class="font10">recombinant </span>
   <span class="font10">relapsed </span>
   <span class="font10">repertoires </span>
   <span class="font10">result </span>
   <span class="font10">selected </span>
   <span class="font10">sequencing </span>
   <span class="font10">signaling </span>
   <span class="font10">sorting </span>
   <span class="font10">successfully </span>
   <span class="font10">targeted </span>
   <span class="font10">technologies </span>
   <span class="font10">transplant </span>
   <span class="font10">yeast </span>
   <span class="font10">yielded </span>
   <span class="font10">(NCT) </span>
   <span class="font10">./j.jmb... </span>
   <span class="font10">Commun </span>
   <span class="font10">Corp. </span>
   <span class="font10">Curr </span>
   <span class="font10">HIV </span>
   <span class="font10">IL-R </span>
   <span class="font10">IgL </span>
   <span class="font10">IgΚ </span>
   <span class="font10">Institute </span>
   <span class="font10">Int </span>
   <span class="font10">Marks </span>
   <span class="font10">Merck </span>
   <span class="font10">Mouse </span>
   <span class="font10">Multiple </span>
   <span class="font10">PBMCs </span>
   <span class="font10">PCSK </span>
   <span class="font10">Rapid </span>
   <span class="font10">Sanofi </span>
   <span class="font10">Squibb </span>
   <span class="font10">Thus, </span>
   <span class="font10">United </span>
   <span class="font10">Yang </span>
   <span class="font10">acute </span>
   <span class="font10">advanced </span>
   <span class="font10">allow </span>
   <span class="font10">artificial </span>
   <span class="font10">available </span>
   <span class="font10">best-selling </span>
   <span class="font10">bind </span>
   <span class="font10">broad </span>
   <span class="font10">carcinoma </span>
   <span class="font10">challenges </span>
   <span class="font10">chromosome </span>
   <span class="font10">chronic </span>
   <span class="font10">cloned </span>
   <span class="font10">companies </span>
   <span class="font10">cytotoxicity </span>
   <span class="font10">designed </span>
   <span class="font10">double; </span>
   <span class="font10">end </span>
   <span class="font10">evaluating </span>
   <span class="font10">evolution </span>
   <span class="font10">expected </span>
   <span class="font10">function </span>
   <span class="font10">global </span>
   <span class="font10">greatly </span>
   <span class="font10">immunization </span>
   <span class="font10">immunized </span>
   <span class="font10">isatuximab </span>
   <span class="font10">melanoma </span>
   <span class="font10">multiple </span>
   <span class="font10">myeloma </span>
   <span class="font10">necrosis </span>
   <span class="font10">nivolumab </span>
   <span class="font10">non-small </span>
   <span class="font10">patents </span>
   <span class="font10">peptide </span>
   <span class="font10">platforms </span>
   <span class="font10">producing </span>
   <span class="font10">proteins </span>
   <span class="font10">randomized </span>
   <span class="font10">rat </span>
   <span class="font10">recent </span>
   <span class="font10">reported </span>
   <span class="font10">severe </span>
   <span class="font10">significant </span>
   <span class="font10">similar </span>
   <span class="font10">small </span>
   <span class="font10">specificity </span>
   <span class="font10">stem </span>
   <span class="font10">therapeutics. </span>
   <span class="font10">van </span>
   <span class="font10">various </span>
   <span class="font10">(NCT). </span>
   <span class="font10">(e.g., </span>
   <span class="font10">./a </span>
   <span class="font10">./j.jim... </span>
   <span class="font10">./pnas. </span>
   <span class="font10">./pnas... </span>
   <span class="font10">Biogen </span>
   <span class="font10">Breast </span>
   <span class="font10">Centocor </span>
   <span class="font10">Co. </span>
   <span class="font10">Development </span>
   <span class="font10">Dyax </span>
   <span class="font10">Expert </span>
   <span class="font10">FDA-approved </span>
   <span class="font10">Fig. </span>
   <span class="font10">Fully </span>
   <span class="font10">Genet </span>
   <span class="font10">George </span>
   <span class="font10">GlaxoSmithKline </span>
   <span class="font10">Guselkumab </span>
   <span class="font10">Hakko </span>
   <span class="font10">High </span>
   <span class="font10">Identification </span>
   <span class="font10">International </span>
   <span class="font10">Lilly </span>
   <span class="font10">Lim </span>
   <span class="font10">NSCLC </span>
   <span class="font10">Necitumumab </span>
   <span class="font10">Neutralizing </span>
   <span class="font10">Non-small </span>
   <span class="font10">Rep </span>
   <span class="font10">Research </span>
   <span class="font10">Rheum </span>
   <span class="font10">Science </span>
   <span class="font10">States </span>
   <span class="font10">Therapy </span>
   <span class="font10">Tsai </span>
   <span class="font10">Using </span>
   <span class="font10">Ustekinumab </span>
   <span class="font10">Young </span>
   <span class="font10">adalimumab </span>
   <span class="font10">anthrax </span>
   <span class="font10">approaches </span>
   <span class="font10">beads </span>
   <span class="font10">blocks </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">chains </span>
   <span class="font10">checkpoints </span>
   <span class="font10">cluster </span>
   <span class="font10">conjugated </span>
   <span class="font10">crucial </span>
   <span class="font10">discovered </span>
   <span class="font10">display, </span>
   <span class="font10">displayed </span>
   <span class="font10">diverse </span>
   <span class="font10">engineered </span>
   <span class="font10">envelope </span>
   <span class="font10">evaluation </span>
   <span class="font10">germline </span>
   <span class="font10">granted </span>
   <span class="font10">healthy </span>
   <span class="font10">higher </span>
   <span class="font10">immunogenic </span>
   <span class="font10">immunotherapy </span>
   <span class="font10">improved </span>
   <span class="font10">induce </span>
   <span class="font10">liposomal </span>
   <span class="font10">loci </span>
   <span class="font10">magnetic </span>
   <span class="font10">microenvironment, </span>
   <span class="font10">migraine </span>
   <span class="font10">naturally </span>
   <span class="font10">non-immunized </span>
   <span class="font10">past </span>
   <span class="font10">patent </span>
   <span class="font10">phages </span>
   <span class="font10">refractory </span>
   <span class="font10">researchers </span>
   <span class="font10">residues </span>
   <span class="font10">resulting </span>
   <span class="font10">showed </span>
   <span class="font10">site </span>
   <span class="font10">solid; </span>
   <span class="font10">structure </span>
   <span class="font10">syncytial </span>
   <span class="font10">synthetic </span>
   <span class="font10">tissue </span>
   <span class="font10">treated </span>
   <span class="font10">vascular </span>
   <span class="font10">widely </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">(CAT, </span>
   <span class="font10">(Humira) </span>
   <span class="font10">(~  kb) </span>
   <span class="font10">./-.CIR-- </span>
   <span class="font10">./mabs. </span>
   <span class="font10">./nbt </span>
   <span class="font10">./science. </span>
   <span class="font10">;():–. </span>
   <span class="font10">ADC </span>
   <span class="font10">AbbVie </span>
   <span class="font10">Academia </span>
   <span class="font10">Accessed </span>
   <span class="font10">Acute </span>
   <span class="font10">Ann </span>
   <span class="font10">Approval </span>
   <span class="font10">Asthma </span>
   <span class="font10">Blood. </span>
   <span class="font10">CAR-T </span>
   <span class="font10">CSC </span>
   <span class="font10">Cells </span>
   <span class="font10">Choi </span>
   <span class="font10">Co., </span>
   <span class="font10">Company </span>
   <span class="font10">Crohn's </span>
   <span class="font10">Discov </span>
   <span class="font10">Disease </span>
   <span class="font10">Dupilumab </span>
   <span class="font10">Ebola </span>
   <span class="font10">Food </span>
   <span class="font10">Furthermore, </span>
   <span class="font10">Future </span>
   <span class="font10">Genentech </span>
   <span class="font10">Golimumab </span>
   <span class="font10">Green </span>
   <span class="font10">Gregory </span>
   <span class="font10">H-C </span>
   <span class="font10">HER </span>
   <span class="font10">Hereditary </span>
   <span class="font10">Hust </span>
   <span class="font10">IL-α </span>
   <span class="font10">Inc., </span>
   <span class="font10">Infect </span>
   <span class="font10">Janssen </span>
   <span class="font10">Jul </span>
   <span class="font10">Kondo </span>
   <span class="font10">Lanadelumab </span>
   <span class="font10">Lancet </span>
   <span class="font10">Lilly/ImClone </span>
   <span class="font10">Lin </span>
   <span class="font10">MERS-CoV </span>
   <span class="font10">Medimmune) </span>
   <span class="font10">Murine </span>
   <span class="font10">PD-L, </span>
   <span class="font10">Pharmacol </span>
   <span class="font10">Plaque </span>
   <span class="font10">Prevention </span>
   <span class="font10">RSV </span>
   <span class="font10">Ramucirumab </span>
   <span class="font10">Recently, </span>
   <span class="font10">Reichert </span>
   <span class="font10">Safety </span>
   <span class="font10">Selection </span>
   <span class="font10">Systems </span>
   <span class="font10">Therapeutics </span>
   <span class="font10">Therefore, </span>
   <span class="font10">VelocImmune </span>
   <span class="font10">Veloclmmune </span>
   <span class="font10">Virol </span>
   <span class="font10">ability </span>
   <span class="font10">action </span>
   <span class="font10">administered </span>
   <span class="font10">advantage </span>
   <span class="font10">angioedema </span>
   <span class="font10">antigen-binding </span>
   <span class="font10">applicable. </span>
   <span class="font10">applied </span>
   <span class="font10">assignee. </span>
   <span class="font10">bacteriophage </span>
   <span class="font10">biological </span>
   <span class="font10">bold </span>
   <span class="font10">called </span>
   <span class="font10">cancer. </span>
   <span class="font10">cancer: </span>
   <span class="font10">cancer; </span>
   <span class="font10">capture </span>
   <span class="font10">category </span>
   <span class="font10">cell-based </span>
   <span class="font10">cellular </span>
   <span class="font10">characteristics </span>
   <span class="font10">characterization </span>
   <span class="font10">chip </span>
   <span class="font10">combinatorial </span>
   <span class="font10">constructed </span>
   <span class="font10">courier; </span>
   <span class="font10">cytotoxic </span>
   <span class="font10">date </span>
   <span class="font10">death </span>
   <span class="font10">develop </span>
   <span class="font10">directed </span>
   <span class="font10">directly </span>
   <span class="font10">disease, </span>
   <span class="font10">em; </span>
   <span class="font10">emergent </span>
   <span class="font10">endogenous </span>
   <span class="font10">especially </span>
   <span class="font10">established </span>
   <span class="font10">followed </span>
   <span class="font10">functions </span>
   <span class="font10">gene-related </span>
   <span class="font10">hypermutation </span>
   <span class="font10">immunogenicity. </span>
   <span class="font10">increased </span>
   <span class="font10">increasing </span>
   <span class="font10">increasingly </span>
   <span class="font10">indications </span>
   <span class="font10">individual </span>
   <span class="font10">induces </span>
   <span class="font10">infants </span>
   <span class="font10">inhibit </span>
   <span class="font10">interaction </span>
   <span class="font10">joining </span>
   <span class="font10">known </span>
   <span class="font10">laser </span>
   <span class="font10">late-stage </span>
   <span class="font10">library. </span>
   <span class="font10">license </span>
   <span class="font10">low </span>
   <span class="font10">lymphoblastic </span>
   <span class="font10">lymphocyte </span>
   <span class="font10">making </span>
   <span class="font10">marketing </span>
   <span class="font10">medical </span>
   <span class="font10">mice, </span>
   <span class="font10">microdissection </span>
   <span class="font10">microengraving </span>
   <span class="font10">modified </span>
   <span class="font10">molecular </span>
   <span class="font10">molecules </span>
   <span class="font10">mutation </span>
   <span class="font10">neck </span>
   <span class="font10">neutralization </span>
   <span class="font10">neutralize </span>
   <span class="font10">obtain </span>
   <span class="font10">obtained </span>
   <span class="font10">outbreak </span>
   <span class="font10">overall </span>
   <span class="font10">particles </span>
   <span class="font10">patients. </span>
   <span class="font10">performed </span>
   <span class="font10">peripheral </span>
   <span class="font10">plaque </span>
   <span class="font10">platform </span>
   <span class="font10">plus </span>
   <span class="font10">possible </span>
   <span class="font10">previously </span>
   <span class="font10">primers </span>
   <span class="font10">programmed </span>
   <span class="font10">psoriatic </span>
   <span class="font10">pt;} </span>
   <span class="font10">random </span>
   <span class="font10">rate </span>
   <span class="font10">reaction </span>
   <span class="font10">rejection </span>
   <span class="font10">relevant </span>
   <span class="font10">second </span>
   <span class="font10">segment </span>
   <span class="font10">segments </span>
   <span class="font10">select </span>
   <span class="font10">single-chain </span>
   <span class="font10">size </span>
   <span class="font10">stability </span>
   <span class="font10">step </span>
   <span class="font10">stringent </span>
   <span class="font10">success </span>
   <span class="font10">therapies </span>
   <span class="font10">time, </span>
   <span class="font10">tool </span>
   <span class="font10">total </span>
   <span class="font10">treatments </span>
   <span class="font10">useful </span>
   <span class="font10">usually </span>
   <span class="font10">versus </span>
   <span class="font10">viral </span>
  </p>
 </body>
</html>
